Gilead makes move in oncology by snaffling Riva from Novartis

pharmafile | January 4, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, Novartis, oncology 

Gilead Sciences have made an ambitious move to boost its oncology business by appointing current head of global oncology development at Novartis, Alessandro Riva. Riva will join Gilead in the role of senior vice president, haematology and oncology therapeutic area head.

Riva had been head of oncology at Novartis for 12 years, developing over 20 cancer compounds which included targeted and immuno-oncology treatments. Gilead will be hoping that this backlog of success carries over to its oncology business, which has struggled of late. Gilead struggled with several drug failures in 2016 whilst also being hit by a $2.54 billion fine for infringing upon patents held by MSD.

“I have always admired Gilead for its scientific focus and data-driven approach to drug development,” said Dr. Riva. “I look forward to working alongside Gilead’s dedicated and passionate colleagues throughout the R&D organization to tackle the cancer research and development challenge with a goal of improving the lives of patients.”

“I am thrilled to welcome Alessandro, who brings a wealth of experience and expertise in hematology/oncology drug development and translational medicine,” said Dr. McHutchison. “His leadership and proven track record developing therapies across the spectrum of hematological malignancies and solid tumors will be instrumental as we continue to grow and advance our pipeline of novel therapeutics for people living with cancer.”

Related Content

Genentech shares positive results from phase 3 trial for breast cancer treatment

Genentech, a member of the Roche Group, has announced positive results from the phase 3 …

Evotec and Dewpoint Therapeutics enter strategic partnership

Evotec and Dewpoint Therapeutics have announced a strategic R&D collaboration for the advancement of Dewpoint’s …

First patient dosed in Transgene and BioInvent’s phase 1 trial

Transgene and BioInvent have announced that the first patient has been treated in the phase …

Latest content